CDXモデル

バイオサイトジェンはB-NDGマウスより構築したCDXモデルでさまざまな薬効研究を行っています。これらのモデルは肺がん、直腸がん、結腸がん、乳がん、脾臓癌、膀胱がん、グリオブラストーマ、肝臓がん、各白血病及びリンパ腫細胞株、ヒトの実腫瘍及び血液腫瘍細胞株などが含めています。弊社はお客様のご依頼に応じて、皮下、in situ、または転移性腫瘍モデルを確立し、薬力学（PD）サービスを提供します。

カタログCDXモデル

	Cell lines	Tumor type	Cell lines	Tumor type
Human solid tumor cell lines	NCI-H1975	Lung carcinoma, non-small cell	ZR-75-1	Breast ductal carcinoma
	HCC827	Lung adenocarcinoma	MDA-MB-231	Breast adenocarcinoma
	NCI-H520	Lung carcinoma	DU4475	Breast carcinoma, triple negative
	A549	Lung carcinoma	MCF7	Mammary gland, breast adenocarcinoma
	NCI-H1781	Lung carcinoma bronchoalveolar	5637	Bladder grade II carcinoma
	HCT-8	Colorectal Ileocecal adenocarcinoma	A431	Epidermoid carcinoma
	HCT-116	Colon carcinoma	LN229	Glioblastoma
	Colo205	Colorectal adenocarcinoma	Miapaca-2	Pancreatic carcinoma
Human blood tumor cell lines	Daudi	Lymphoma,	NAMALWA	Burkitt’s lymphoma
	KG-1	Leukemia, acute myelogenous (AML)	Kasumi-1	Leukemia, acute myeloblastic (AML)
	Raji	Lymphoma, Burkitt’s	SU-DHL-1	Large cell lymphoma, Diffuse histiocytic lymphoma
	K562	Leukemia (CML)	MV4-11	Peripheral blood biphenotypic B myelomonocytic leukemia

ルシフェラーゼマーカー細胞株のCDXモデル

No.	Cell name	Cancer type
B-HCL-013	B-luciferase-GFP Raji Cell Line	Lymphoma, Burkitt’s
B-MCL-001	B-luciferase-GFP HT-29 Cell Line	Colorectal adenocarcinoma
B-MCL-002	B-luciferase-GFP H-1975 Cell Line	Lung carcinoma, non-small cell
B-HCL-014	B-luciferase K562 Cell Line	Leukemia (CML)
B-HCL-015	B-luciferase MIA PaCa-2 Cell Line	Pancreatic carcinoma
B-HCL-010	B-luciferase U-87MG cell line	Glioblastoma

CDXマウスモデルの腫瘍成長曲線

事例1：HT-29-GFP Luciferase（ルシフェラーゼ）細胞を移植後第6/16/28日のNOD-scidマウスの生体イメージング

A) The mouse on the left was injected with 5 x 106 cells. The mouse on the right was injected with 5 x 105 (B) Signal intensity and tumor size graph.

事例2：4T1-Luciferase（ルシフェラーゼ）細胞の移植の後、第7/14/21日のNOD-scidマウスの生体イメージング

(A) The mouse on the left was injected with 5 x 106 cells; the mice on right was injected with 5 x 105 cells. (B) Signal intensity and tumor size graph.

事例3：ヒトB細胞リンパ腫のCDXモデル

Raji cells (5×10⁶) were injected into B-NDG, NOD-scid and BALB/C nude mice. (A) Kaplan-Merier survival curves. (B) Relative body weight change. (C) Percentage of human cells in mouse peripheral blood quantified by q-PCR. (D) Liver tumor nodules. (E) Immunohistochemical staining of livers and spleens.

B-NDGモデルによる薬物効果の評価

研究事例1

Raji-Fluc cells (5 x 10⁵) were injected into B-NDG mice. Antibody X was administered on specified days. (A) Representative in vivo imaging recorded at different time points to monitor tumor progression. (B) Tumor load (as indicated by luciferase activity) kinetic curves post antibody treatment. Early dosing on day 3 in addition to day 10 resulted in robust tumor growth inhibition. In contrast, a single dose at day 10 had little effect.

研究事例2

Humanized B-NDG mice engrafted with human CD34+ HSC were intravenously injected with 5 x 10⁵ Raji-Fluc cells. Five days after Raji-Fluc cells implantation, mice were treated with anti-human PD-1 antibody. (A) Images of tumor load as indicated by luciferase activity. Tumor growth was dramatically inhibited by the human PD-1 antibody at day 7. RC=Raji-Fluc + Control. PDH=Antibody X + Humanized Mice. Naive B-NDG=Untreated Group.